Biblio

Author Title Type [ Year(Desc)]
Filters: Author is Lee, Je-Jung  [Clear All Filters]
2014
Jung S-H, Yang D-H, Ahn J-S, Kim Y-K, Kim H-J, Lee J-J. Advanced lytic lesion is a poor mobilization factor in peripheral blood stem cell collection in patients with multiple myeloma. J Clin Apher. 2014.
Ahn J-S, Yang D-H, Jung S-H, Lee J-J, Kim I, Park S, Chung JSeop, Shin H-J, Kim D-Y, Lee K-H, et al. Clinical Efficacy of Mitoxantrone and Ara-C with or without Etoposide Salvage Chemotherapy in Adult Patients with Relapsed or Refractory Acute Lymphoblastic Leukemia: Retrospective Multicenter Study of the Korean Adult ALL Working Party. Acta Haematol. 2014;133(1):91-97.
Ahn S-Y, Jung S-H, Joo YDon, Lee WSik, Lee SMin, Choi CWon, Kim SJin, Kim K, Lee J-J. Early response-based intensification of primary therapy in newly diagnosed multiple myeloma patients who are eligible for autologous stem cell transplantation: phase II study. Ann Hematol. 2014.
Benboubker L, Dimopoulos MA, Dispenzieri A, Catalano J, Belch AR, Cavo M, Pinto A, Weisel K, Ludwig H, Bahlis N, et al. Lenalidomide and Dexamethasone in Transplant-Ineligible Patients with Myeloma. N Engl J Med. 2014;371(10):906-917.
2016
Jun CHwan, Kim BSuk, Oak CYoung, Lee DHyeon, Cho E, Cho SBum, Choi SKyu, Park CHwan, Joo YEun, Lee J-J, et al. HBV reactivation risk factors in patients with chronic HBV infection with low replicative state and resolved HBV infection undergoing hematopoietic stem cell transplantation in Korea. Hepatol Int. 2016.
2018
Lee G-W, Park SWoo, Go S-I, Kim H-G, Kim MKyoung, Min C-K, Kwak J-Y, Bae S-B, Yoon S-S, Lee J-J, et al. The Derived Neutrophil-to-Lymphocyte Ratio Is an Independent Prognostic Factor in Transplantation Ineligible Patients with Multiple Myeloma. Acta Haematol. 2018;140(3):146-156.
2019
Bastidas A, de la Serna J, Idrissi MEl, Oostvogels L, Quittet P, López-Jiménez J, Vural F, Pohlreich D, Zuckerman T, Issa NC, et al. Effect of Recombinant Zoster Vaccine on Incidence of Herpes Zoster After Autologous Stem Cell Transplantation: A Randomized Clinical Trial. JAMA. 2019;322(2):123-133.
Ahn J-S, Kim TH, Kim Y-K, Cho Y-C, Cho S, Jung S-H, Ahn S-Y, Jung S-Y, Yang D-H, Lee J-J, et al. Remission clone in acute myeloid leukemia shows growth advantage after chemotherapy but is distinct from leukemic clone. Exp Hematol. 2019.
2020
Ahn J-S, Kim TH, Jung S-H, Ahn S-Y, Jung S-Y, Song G-Y, Kim M, Yang D-H, Lee J-J, Choi SH, et al. Allogeneic transplant can abrogate the risk of relapse in the patients of first remission acute myeloid leukemia with detectable measurable residual disease by next-generation sequencing. Bone Marrow Transplant. 2020.
2023
Kim M, Lee J-J, Min C-K, Lee JYun, Jo J-C, Yoon S-S, Lim S-N, Do YRok, Kim K, Lee JHoon, et al. Busulfan plus melphalan versus high-dose melphalan as a conditioning regimen for autologous stem cell transplantation in multiple myeloma with high-risk features (KMM 2015). Ann Hematol. 2023.
2024
Shin H-J, Kim D-Y, Kim K, Min C-K, Lee J-J, Mun Y-C, Lee W-S, Lim S-N, Kim JSeok, Moo JHo, et al. Nation-Wide Retrospective Analysis of Allogeneic Stem Cell Transplantation in Patients with Multiple Myeloma: A Study from Korean Multiple Myeloma Working Party (KMM1913). Cancer Res Treat. 2024.